Suggested remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for treating moderate to severe indolent systemic mastocytosis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6578
Provisional Schedule
- Committee meeting: 1:
- 05 May 2026
- Expected publication:
- 01 July 2026
- Expected publication:
- 26 August 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Blueprint Medicines (avapritinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Chronic Lymphocytic Leukaemia Support Association
- Chronic Myeloid Leukaemia Support Group
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- MPN Voice
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Mastocytosis support group
- Professional groups
- Association of Cancer Physicians
- Association of Genetic Nurses and Counsellors
- British Association of Dermatologists
- British Blood Transfusion Society
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Allergy and Clinical Immunology
- British Society for Genetic Medicine
- British Society for Haematology
- British Society for Immunology
- British Society of Interventional Radiology
- Cancer Research UK
- Joint Committee on Immunology and Allergy
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Hospital Information Services - Jehovah's Witnesses
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Blood and Transplant
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematological Malignancies Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Leukaemia UK
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 September 2025 | Invitation to participate |
| 31 July 2025 - 29 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 31 July 2025 | In progress. Scoping commenced. |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual